Preliminary clinical outcomes and adoption of continuous glucose monitoring following reimbursement implementation in patients with type 1 diabetes in Thailand
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Continuous glucose monitoring (CGM) improved glycemic outcomes in type 1 diabetes (T1D) patients, especially with hybrid closed-loop systems. However, CGM adoption in Thailand remains low, necessitating improved access and adherence strategies.
Area Of Science
- Endocrinology
- Metabolic Diseases
- Medical Technology
Background
- Continuous glucose monitoring (CGM) is a clinical guideline recommendation for managing type 1 diabetes (T1D).
- CGM was recently integrated into Thailand's Universal Healthcare Coverage (UHC) program.
- Evaluating preliminary outcomes and adoption of CGM in Thailand is crucial.
Purpose Of The Study
- To assess glycemic outcomes before and after CGM implementation under the UHC program.
- To compare outcomes across Self-Monitoring Blood Glucose (SMBG), CGM, Open Loop Insulin Pump, and Hybrid Closed-Loop (HCL) systems.
- To analyze CGM adherence and device adoption rates.
Main Methods
- A retrospective-prospective study design was employed.
- Data collected included demographics, HbA1c levels, and CGM parameters.
- 142 T1D patients were analyzed across four treatment groups.
Main Results
- The Hybrid Closed-Loop (HCL) system demonstrated the most significant HbA1c reduction (-0.99%), particularly in patients under 18 (-1.21%).
- CGM users showed a trend towards improved HbA1c (-0.29%) and time in range (TIR) (69.2% vs. 47.1%).
- Preliminary CGM uptake was 12%, with HCL users showing higher TIR and sensor adherence.
Conclusions
- The HCL system significantly enhances glycemic control, especially in pediatric T1D patients.
- Low CGM adoption rates highlight challenges with access, reimbursement, and adherence.
- Strategies to expand CGM access and improve adherence are needed for broader T1D management.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...